Press Releases
BullFrog AI Partners with the Sage Group to Explore JV Opportunities to Advance its Oncology Assets
BullFrog’s oncology assets have been acquired through exclusive licenses with Johns Hopkins University (JHU) and include a phase 2 ready asset and a preclinical prodrug asset
26 April 2023 -- Maryland, US -- BullFrog AI Holdings, Inc, a digital technology company using machine learning to usher in a new era of precision medicine, today announced a strategic partnership with the Sage Group, a leader in the provision of strategic and transactional advice to healthcare and life science companies in the pharmaceutical, diagnostics, medical device, biotech, regenerative medicine and cell and gene therapy fields.
The engagement will focus on seeking joint venture (JV) opportunities to further advance BullFrog AI’s phase 2 ready asset targeting glioblastoma, an aggressive form of brain cancer, as well as the company’s preclinical prodrug asset. The partnership will give BullFrog AI access to the Sage Group’s clinical and regulatory expertise, capital resources and network of contacts, including innovators and large pharma.
"Glioblastoma is one of the deadliest forms of cancer, with a five-year survival rate of less than seven percent,” said BullFrog AI’s founder and CEO, Vin Singh. “With the Sage Group’s support, we look forward to identifying the right partner to help us advance clinical development of our oncology programs globally in an effort to bring a revolutionary new treatment option to glioblastoma patients.”
The market for glioblastoma treatment is expected to surpass $10bn by 2030, up from $5.1bn in 2020, according to a 2022 analysis by a Vision Research Report. BullFrog AI has previously announced the grant of exclusive licenses from JHU for a novel formulation of mebendazole that has been evaluated in two clinical trials for glioblastoma, and for a novel prodrug of mebendazole with improved bioavailability.
About BullFrog AI
BullFrog AI is a digital technology company using machine learning (ML) to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ AI platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics and impacting the lives of countless patients that may seek to receive the therapies they need. Visit BullFrogAI at www.bullfrogai.com.
About The Sage Group
Sage Group is a leader in the provision of strategic and transactional advice to healthcare and life science companies in the diagnostics, medical device, pharmaceutical, biotechnology, life science and analytical instrument fields. We transform ideas, strategy and technology into shareholder value. We turn ambitions into results and achievement of success. We have operated globally for more than 28 years with considerable deal flow and achieved extensive commercial success for our clients. Visit: www.sagehealthcare.com.
BullFrog’s oncology assets have been acquired through exclusive licenses with Johns Hopkins University (JHU) and include a phase 2 ready asset and a preclinical prodrug asset
26 April 2023 -- Maryland, US -- BullFrog AI Holdings, Inc, a digital technology company using machine learning to usher in a new era of precision medicine, today announced a strategic partnership with the Sage Group, a leader in the provision of strategic and transactional advice to healthcare and life science companies in the pharmaceutical, diagnostics, medical device, biotech, regenerative medicine and cell and gene therapy fields.
The engagement will focus on seeking joint venture (JV) opportunities to further advance BullFrog AI’s phase 2 ready asset targeting glioblastoma, an aggressive form of brain cancer, as well as the company’s preclinical prodrug asset. The partnership will give BullFrog AI access to the Sage Group’s clinical and regulatory expertise, capital resources and network of contacts, including innovators and large pharma.
"Glioblastoma is one of the deadliest forms of cancer, with a five-year survival rate of less than seven percent,” said BullFrog AI’s founder and CEO, Vin Singh. “With the Sage Group’s support, we look forward to identifying the right partner to help us advance clinical development of our oncology programs globally in an effort to bring a revolutionary new treatment option to glioblastoma patients.”
The market for glioblastoma treatment is expected to surpass $10bn by 2030, up from $5.1bn in 2020, according to a 2022 analysis by a Vision Research Report. BullFrog AI has previously announced the grant of exclusive licenses from JHU for a novel formulation of mebendazole that has been evaluated in two clinical trials for glioblastoma, and for a novel prodrug of mebendazole with improved bioavailability.
About BullFrog AI
BullFrog AI is a digital technology company using machine learning (ML) to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ AI platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics and impacting the lives of countless patients that may seek to receive the therapies they need. Visit BullFrogAI at www.bullfrogai.com.
About The Sage Group
Sage Group is a leader in the provision of strategic and transactional advice to healthcare and life science companies in the diagnostics, medical device, pharmaceutical, biotechnology, life science and analytical instrument fields. We transform ideas, strategy and technology into shareholder value. We turn ambitions into results and achievement of success. We have operated globally for more than 28 years with considerable deal flow and achieved extensive commercial success for our clients. Visit: www.sagehealthcare.com.
Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.